|
🐜
|
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
29 auth.
D. M. van der Heijde,
S. Ramiro,
R. Landewé,
X. Baraliakos,
F. E. Van den Bosch,
A. Sepriano,
A. Regel,
A. Ciurea,
H. Dagfinrud,
M. Dougados,
F. V. van Gaalen,
P. Géher,
I. E. van der Horst-Bruinsma,
R. Inman,
Merryn Jongkees,
...
U. Kiltz,
T. Kvien,
P. Machado,
H. Marzo-Ortega,
A. Moltó,
V. Navarro-Compán,
S. Ozgoçmen,
F. Pimentel-Santos,
J. Reveille,
M. Rudwaleit,
J. Sieper,
P. Sampaio-Barros,
D. Wiek,
J. Braun
|
10 |
2017 |
10
🐜
|
|
🐜
|
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
28 auth.
L. Gossec,
X. Baraliakos,
A. Kerschbaumer,
M. D. de Wit,
I. McInnes,
M. Dougados,
J. Primdahl,
D. McGonagle,
D. Aletaha,
A. Balanescu,
P. Bálint,
H. Bertheussen,
W. Boehncke,
G. Burmester,
J. Cañete,
...
N. Damjanov,
T. Kragstrup,
T. Kvien,
R. Landewé,
R. Lories,
H. Marzo-Ortega,
D. Poddubnyy,
Santiago Rodrigues Manica,
G. Schett,
D. Veale,
F. E. Van den Bosch,
D. M. van der Heijde,
J. Smolen
|
9 |
2020 |
9
🐜
|
|
🐜
|
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
37 auth.
J. Smolen,
Monika Schöls,
J. Braun,
M. Dougados,
O. FitzGerald,
D. Gladman,
A. Kavanaugh,
R. Landewé,
P. Mease,
J. Sieper,
T. Stamm,
M. D. de Wit,
D. Aletaha,
X. Baraliakos,
N. Betteridge,
...
F. E. Van den Bosch,
L. Coates,
P. Emery,
L. Gensler,
L. Gossec,
P. Helliwell,
Merryn Jongkees,
T. Kvien,
R. Inman,
I. McInnes,
M. Maccarone,
P. Machado,
A. Moltó,
A. Ogdie,
D. Poddubnyy,
C. Ritchlin,
M. Rudwaleit,
A. Tanew,
B. Thio,
D. Veale,
K. de Vlam,
D. M. van der Heijde
|
9 |
2017 |
9
🐜
|
|
🐜
|
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
27 auth.
M. Ward,
A. Deodhar,
E. Akl,
A. Lui,
J. Ermann,
L. Gensler,
Judith A. Smith,
D. Borenstein,
J. Hiratzka,
P. Weiss,
R. Inman,
V. Majithia,
N. Haroon,
W. Maksymowych,
J. Joyce,
...
B. M. Clark,
R. Colbert,
M. Figgie,
D. Hallegua,
P. Prete,
J. Rosenbaum,
Judith A. Stebulis,
F. E. Van den Bosch,
David T. Y. Yu,
Amy S. Miller,
J. Reveille,
L. Caplan
|
8 |
2016 |
8
🐜
|
|
🐜
|
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
32 auth.
J. Smolen,
J. Braun,
M. Dougados,
P. Emery,
O. FitzGerald,
P. Helliwell,
A. Kavanaugh,
T. Kvien,
R. Landewé,
T. Luger,
P. Mease,
I. Olivieri,
J. Reveille,
C. Ritchlin,
M. Rudwaleit,
...
M. Schoels,
J. Sieper,
M. D. de Wit,
X. Baraliakos,
N. Betteridge,
R. Burgos-Vargas,
E. Collantes-Estévez,
A. Deodhar,
D. Elewaut,
L. Gossec,
Merryn Jongkees,
M. Maccarone,
K. Redlich,
F. E. Van den Bosch,
J. Wei,
K. Winthrop,
D. M. van der Heijde
|
8 |
2013 |
8
🐜
|
|
🐜
|
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
33 auth.
S. Ramiro,
E. Nikiphorou,
A. Sepriano,
A. Ortolan,
C. Webers,
X. Baraliakos,
R. Landewé,
F. E. Van den Bosch,
B. Boteva,
A. Bremander,
P. Carron,
A. Ciurea,
F. V. van Gaalen,
P. Géher,
L. Gensler,
...
J. Hermann,
M. de Hooge,
M. Hušáková,
U. Kiltz,
C. López-Medina,
P. Machado,
H. Marzo-Ortega,
A. Moltó,
V. Navarro-Compán,
M. Nissen,
F. Pimentel-Santos,
D. Poddubnyy,
F. Proft,
M. Rudwaleit,
Mark Telkman,
S. Zhao,
N. Ziadé,
D. van der Heijde
|
8 |
2022 |
8
🐜
|
|
🐜
|
Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group
22 auth.
R. Lambert,
P. Bakker,
D. van der Heijde,
U. Weber,
M. Rudwaleit,
K. Hermann,
J. Sieper,
X. Baraliakos,
A. Bennett,
J. Braun,
...
R. Burgos-Vargas,
M. Dougados,
S. Pedersen,
A. Jurik,
W. Maksymowych,
H. Marzo-Ortega,
M. Østergaard,
D. Poddubnyy,
M. Reijnierse,
F. E. Van den Bosch,
I. E. van der Horst-Bruinsma,
R. Landewé
|
8 |
2016 |
8
🐜
|
|
🐜
|
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
11 auth.
L. Moreland,
R. Alten,
F. E. Van den Bosch,
T. Appelboom,
M. Léon,
P. Emery,
...
S. Cohen,
M. Luggen,
W. Shergy,
I. Nuamah,
J. Becker
|
8 |
2002 |
8
🐜
|
|
🦁
|
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
7 auth.
F. E. Van den Bosch,
E. Kruithof,
D. Baeten,
A. Herssens,
F. de Keyser,
H. Mielants,
...
E. Veys
|
8 |
2002 |
8
🦁
|
|
🦁
|
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study
F. E. Van den Bosch,
E. Kruithof,
D. Baeten,
F. de Keyser,
H. Mielants,
E. Veys
|
8 |
2000 |
8
🦁
|
|
🐜
|
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort
7 auth.
S. Ramiro,
D. M. van der Heijde,
A. V. van Tubergen,
C. Stolwijk,
M. Dougados,
F. E. Van den Bosch,
...
R. Landewé
|
8 |
2014 |
8
🐜
|
|
🐜
|
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
13 auth.
P. Mease,
P. Ory,
Jt Sharp,
C. Ritchlin,
F. E. Van den Bosch,
F. Wellborne,
C. Birbara,
Gtd Thomson,
Rj Perdok,
J. Medich,
...
Rl Wong,
D. Gladman,
P. Mease
|
8 |
2008 |
8
🐜
|
